Is There a Higher Risk of CNS Adverse Events for PI Monotherapy Versus Triple Therapy? A Review of Results From Randomized Clinical Trials

REFERENCES

• Pulido F, Matarranz M, Rodriguez-Rivera V, Fiorante S, Hernando A. Boosted protease inhibitor monotherapy: What have we learned after seven years of research? AIDS Rev. 2010;12: 127–134
   PubMed Web of Science ®Google Scholar
• Battegay M, Bucher H. Antiretroviral monotherapy: Should we abandon the principles of successful antiretroviral therapy? AIDS. 2010;24:1057-1059.
   Google Scholar
• Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: A systematic review. AIDS. 2009;23:279–291.
   PubMed Web of Science ®Google Scholar
• Mathis S, Khanlari B, Pulido F, et al. Effectiveness of pro-tease inhibitor monotherapy versus combination antiret-roviral maintenance therapy: A meta-analysis. PLoS One. 2011; 6(7): e22003.
   PubMed Web of Science ®Google Scholar
• Arribas J, Clumeck N, Nelson M, et al. The MONET trial: Week 144 analysis of efficacy of darunavir/ritonavir mono-therapy versus DRV/r + 2 NRTIs, for patients with HIV RNA <50 copies/mL at baseline. HIV Med. 2012;13:398–405.
   PubMed Web of Science ®Google Scholar
• Katlama C, Valentin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: A randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS. 2010 ;24(15):2365–2374.
   PubMed Web of Science ®Google Scholar
• Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleo-side analogues for maintenance therapy of HIV. AIDS. 2008 ;22:F1–F9.
   PubMed Web of Science ®Google Scholar
• Arribas J, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr. 2009;51(2):147–152.
   PubMed Web of Science ®Google Scholar
• Gilks C, Walker S, Dunn D, et al. Lopinavir/ritonavir mono-therapy after 24 weeks of second-line antiretroviral therapy in Africa: A randomized controlled trial (SARA) [published online ahead of print July 19, 2012]. Antivir Ther. doi: 10.3851/IMP2253.
   Google Scholar
• Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ ritonavir monotherapy versus tenofovir/lopinavir/ritonavir in patients failing NNRTI-regimens: The HIV STAR study [published online ahead of print July 2, 2012]. Antivir Ther. doi: 10.3851/IMP2443.
   Google Scholar
• Paton N, Kityo C, Hoppe A, et al. A pragmatic randomized controlled strategy trial of three second-line treatment options for use in public health rollout programme set-tings: The Europe-Africa Research Network for Evalua-tion of Second-Line Therapy (EARNEST) Trial [abstract WELBB02]. Presented at: 7th International Conference on HIV Pathogenesis, Treatment and Prevention; June 2013; Kuala Lumpur, Malaysia.
   Google Scholar
• Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas, J. Protease inhibitor monotherapy and the CNS: Peace of mind? J Antimicrob Chemother. 2011;66(9):1954–1962.
   PubMed Web of Science ®Google Scholar
• Arribas J, Hill A. Neurocognitive disorders during antiret-roviral treatment, despite full HIV RNA suppression. HIV Ther. 2010;4(3):1758.
   Google Scholar
• Gisslen M, Fuchs D, Hagberg L, Svennerholm B, Zetter-rberg H. Cerebrospinal fluid viral breakthrough in two HIV infected subjects on darunavir/ritonavir monotherapy [published ahead of print July 9, 2012]. Scand J Infect Dis. doi: 10.3109/00365548.2012.690526.
   Web of Science ®Google Scholar
• Pasquet A, Ajana F, Melliez H, Guirca C, Poissy J, Yaz-danpanah Y. Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load. AIDS. 2012; 26:1726–1727.
   PubMed Web of Science ®Google Scholar
• Canestri A, Lescure X, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiv-ing suppressive antiretroviral therapy. Clin Infect Dis. 2010;50:773–778.
   PubMed Web of Science ®Google Scholar
• Winston A, Moecklinghoff C, Hill A. Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues. Int J STD AIDS. 2012;23:225–226.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Zona S, Cossarizza A, et al. Impact of switch-ing to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in virologically suppressed HIV-infected adults. The MONARCH random-ized controlled trial. Presented at: European AIDS Confer-ence; October 2011; Belgrade, Serbia. Abstract PE7.5/4.
   Google Scholar
• Arribas J, Pulido F, Delgado R, et al. Lopinavir/ritona-vir as single-drug therapy for maintenance of HIV-1 viral suppression. J Acquir Immune Defic Syndr. 2005; 40:280–287.
   PubMed Web of Science ®Google Scholar
• Nunes E, Santini de Olveira M, Mercon M, et al. Mono-therapy with lopinavir/ritonavir as maintenance after HIV-1 viral suppression: Results of a 96-week randomised, con-trolled, open-label pilot trial (KalMo Study). HIV Clin Trials. 2009;10:368–374.
   PubMed Web of Science ®Google Scholar
• Bernardino J, Pulido F, Martinez E, et al. Switching to lopi-navir-ritonavir with or without abacavir and lamivudine in lipoatrophic patients treated with zidovudine/lamivudine/ abacavir. J Antimicrob Chemother. 2013;11:1373–1381.
   Web of Science ®Google Scholar
• Meynard J, Bouteloup V, Landman R, et al. Lopinavir/rito-navir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: The KALE-SOLO trial. J Antimicrob Chemother. 2010;65:2436–2444.
   PubMed Web of Science ®Google Scholar
• Waters L, Jackson A, Singh K, et al. A randomised trial of lopinavir/ritonavir (LPV/r) monotherapy vs continued HAART in patients on suppressive therapy. Presented at: AIDS 2008 - XVII International AIDS Conference; July 2008; Vienna, Austria. Abstract CDB0193.
   Google Scholar
• Cahn P, Andrade-Villanueva J, Sierra-Madero J, et al. Efficacy and safety of lopinavir/ritonavir monotherapy vs standard of care consisting of a protease inhibitor and two NRTIs in adults with HIV-1 [abstract]. Presented at: European AIDS Clincal Society Conference; October 2009; Cologne/Bonn, Germany.
   Google Scholar
• Gutmann C, Cusini A, Gunthard H, et al. Randomised, controlled study demonstrating failure of LPV/r monother-apy in HIV: The role of compartment and CD4-nadir. AIDS. 2010;24:2347–2354.
   PubMed Web of Science ®Google Scholar
• Winston A, Puls R, Kerr S, et al. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: A randomized, con-trolled study. HIV Med. 2012;13:245–251.
   PubMed Web of Science ®Google Scholar
• Bunupuradah T, Chetchotisakd P, Jirajariyavaj S, et al. Neurocognitive impairments in patients using lopinavir/ ritonavir monotherapy versus lopinavir/ritonavir-based HAART. Presented at: 19th Conference on Retroviruses and Opportunistic Infections (CR01); March 2012; Seattle, WA. Abstract 479.
   Google Scholar
• Santos J, Munoz-Moreno J, Molto J, et al. Long-term monotherapy with lopinavir/ritonavir (>2 years) is not asso-ciated with greater HIV-associated neurocognitive impair-ment. Presented at:19th Conference on Retroviruses and Opportunistic Infections (CR01); March 2012; Seattle, WA. Abstract E–117.
   Google Scholar
• Perez-Valero I, Gonzalez-Baeza A, Estebanez M, et al. Prolonged treatment with boosted protease inhibitor monotherapy is not associated with a higher rate of neu-rocognitive impairment than triple-drug HAART [abstract]. Presented at: 11th Conference on HIV Treatment; 2012; Glasgow, United Kingdom.
   Google Scholar
• UK Medical Research Council. A randomised controlled trial of a strategy of switching to boosted protease inhibi-tor monotherapy versus continuing combination antiret-roviral therapy for the long-term management of HIV-1 infected patients who have achieved sustained virological suppression on highly-active antiretroviral therapy C PIVOT trial. http://www.controlled-trials.com/ISRCTN04857074. Accessed May 13, 2011.
   Google Scholar
• PIVOT Trial Investigators. CNS sub-study background and design. Central nervous www.pivot-trial.org/cns_substudy/background_design.aspx. Accessed October 8, 2012.
   Google Scholar
• PROTEA Trial Investigators. A clinical trial comparing the efficacy of darunavir/ritonavir monotherapy versus a triple combination therapy containing darunavir/ritonavir and 2 nucleoside/nucleotide reverse transcriptase inhibi-tors in patients with undetectable plasma HIV-1 RNA on current treatment (PROTEA). http://clinicaltrials.gov/ct2/results?term=darunavir+protea. Accessed October 8, 2012,
   Google Scholar
• Germans Trias i Pujol Hospital. Clinical study to evaluate the efficacy and safety of lopinavir/ritonavir monotherapy versus darunavir/ritonavir monotherapies as simplification switching strategies of PI/NNRTI-triple therapy based-reg-imens. http://clinicaltrials.gov/ct2/show/NCT00994344?term=darunavir+lopinavir+monotherapy&rank=1. Accessed October 8, 2012.
   Google Scholar